مقالههای Azam Hemmati
توجه: محتویات این صفحه به صورت خودکار پردازش شده و مقالههای نویسندگانی با تشابه اسمی، همگی در بخش یکسان نمایش داده میشوند.
۱Cloning, Expression and Characterization of Recombinant Human Fc Receptor Like 1, 2 and 4 Molecules
نویسنده(ها): Mahdi Shabani، Azam Hemmati، Mahdi Zandemami، Jalal Khoshnoodi، Mahmood Jeddi، TEHRANI، Hodjatallah Rabbani، Zahra Amirghofran، Fazel Shokri
اطلاعات انتشار: Iranian Journal of Biotechnology، يازدهم،شماره۳(پياپي ۴۳)، ۲۰۱۳، سال ۰
تعداد صفحات: ۱۱
Background: The Fc receptor like (FCRL) molecules belong to the immunoglobulin (Ig) superfamily with potentially immunoregulatory function. Among the FCRL family FCRL2 and 4 are predominantly expressed on memory B cells and FCRL1 is a pan– B cell marker. To date، no ligand has been identified for the human FCRL1، 2 and 4 molecules..Objectives: Cloning، expression، purification and structural analysis of the extracellular domain of human FCRL1، 2 and 4 proteins..Materials and Methods: In this study، the extracellular part of human FCRL1، 2 and 4 were subcloned into prokaryotic expression vectors pET–28b (+) and transformed into BL21–DE3 E.coli strain. Protein expression was optimized by fine adjustments such as induction time، incubation temperature and expression hosts. Recombinant FCRL proteins were purified by metal affinity chromatography using Ni–NTA resin. Purified FCRL proteins were further characterized by SDS–PAGE and immunoblotting using His–tag and FCRL specific polyclonal antibodies..Results: Our results demonstrated that FCRL1، 2 and 4 were successfully expressed in pET–28b (+) vector. Optimization of the expression procedure showed that IPTG induction at OD600 = 0.9 and overnight incubation at 37˚C resulted in the highest expression levels of FCRL proteins ranging from approximately 15% (FCRL1) to 25% (FCRL2 and 4) of the total bacterial lysate proteins..Conclusions: These purified recombinant proteins are potentially a valuable tool for investigating the immunoregulatory function of FCRL molecules and the production of specific mAbs for immunotherapeutic interventions..
نمایش نتایج ۱ تا ۱ از میان ۱ نتیجه